ERBB2 and neoplasm: We found numerically more RFI events at 5 years in patients with SHR-positive, HER2-negative and PIK3CA-mutated tumours than in patients with PIK3CA-wildtype tumours (7.9% and 6.0%, resp., Fig. S1A).